Prognostic Value of Iodine-123 Metaiodobenzylguanidine Imaging in Patients with Heart Failure

Overview

Journal Exp Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2009 Jul 31

PMID 19641657

Citations 5

Authors

Shinro Matsuo

Yasuyuki Nakamura

Tetsuya Matsumoto

Ichiro Nakae

Kiyoshi Murata

Minoru Horie

Affiliations

Soon will be listed here.

Abstract

Abnormalities of myocardial sympathetic nerve function were reported in congestive heart failure (CHF). To assess myocardial sympathetic nerve function, we obtained metaiodobenzylguanidine (MIBG) images 15 min and 180 min after the injection of iodine-123 MIBG at a dose of 111 MBq and calculated the ratio of heart to mediastinum count (H/M) and the washout rates (WRs) in 59 consecutive patients with CHF and age-matched subjects without CHF (n=23). The plasma levels of B-type natriuretic peptide were measured. H/M ratio was significantly lower in the CHF group (1.8+/-0.9) than in the control group (2.6+/-0.4; P<0.01). WR was higher in the CHF group (38+/-4%) than in the control group (28+/-3%; P<0.01). H/M was inversely correlated with the plasma B-type natriuretic peptide (r=-0.46, P<0.05). Eighteen patients suffered cardiac events (two deaths, 16 hospitalizations) during a mean follow-up period of three years. Kaplan-Meier analysis showed that a low H/M was associated with a poor prognosis in patients with CHF. These findings indicate that the H/M ratio on MIBG imaging is a useful predictor of mortality and morbidity in patients with CHF.

Citing Articles

Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity.

Dimiene I, Hoppenot D, Vajauskas D, Padervinskiene L, Rimkunas A, Zemaitis M J Clin Med. 2024; 13(10).

PMID: 38792478 PMC: 11121926. DOI: 10.3390/jcm13102937.

Significance of I-mIBG SPECT cardiac imaging in heart failure.

Bandyopadhyay D, Gerard P, Jain D J Nucl Cardiol. 2021; 29(4):1810-1812.

PMID: 33948895 DOI: 10.1007/s12350-021-02643-5.

Clinical use of nuclear cardiology in the assessment of heart failure.

Matsuo S, Nakajima K, Kinuya S World J Cardiol. 2010; 2(10):344-56.

PMID: 21160612 PMC: 2999043. DOI: 10.4330/wjc.v2.i10.344.

Standardization of the heart-to-mediastinum ratio of 123I-labelled-metaiodobenzylguanidine uptake using the dual energy window method: feasibility of correction with different camera-collimator combinations.

Matsuo S, Nakajima K, Okuda K, Kawano M, Ishikawa T, Hosoya T Eur J Nucl Med Mol Imaging. 2008; 36(4):560-6.

PMID: 18989667 DOI: 10.1007/s00259-008-0971-2.

The role of impaired sympathetic nerve function in enhancing coronary vasoconstriction in patients with hypertrophic cardiomyopathy.

Matsuo S, Matsumoto T, Nakae I, Horie M Exp Clin Cardiol. 2008; 12(1):37-41.

PMID: 18650978 PMC: 2359623.

References

Matsuo S, Takahashi M, Nakamura Y, Kinoshita M . Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in silent myocardial ischemia. J Nucl Med. 1996; 37(5):712-7. View

Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990; 82(5):1730-6. DOI: 10.1161/01.cir.82.5.1730. View

Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M . Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol. 2002; 9(4):407-12. DOI: 10.1067/mnc.2002.122765. View

Taki J, Nakajima K, Bunko H, Simizu M, Muramori A, Hisada K . Whole-body distribution of iodine 123 metaiodobenzylguanidine in hypertrophic cardiomyopathy: significance of its washout from the heart. Eur J Nucl Med. 1990; 17(5):264-8. DOI: 10.1007/BF00812368. View

Matsuo S, Nakamura Y, Matsui T, Matsumoto T, Kinoshita M . Detection of denervated but viable myocardium in cardiac sarcoidosis with I-123 MIBG and Tl-201 SPECT imaging. Ann Nucl Med. 2001; 15(4):373-5. DOI: 10.1007/BF02988246. View

Glowniak J, Kilty J, Amara S, HOFFMAN B, Turner F . Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993; 34(7):1140-6. View

Sahn D, DeMaria A, Kisslo J, Weyman A . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58(6):1072-83. DOI: 10.1161/01.cir.58.6.1072. View

Matsuo S, Nakamura Y, Takahashi M, Matsui T, Kusukawa J, Yoshida S . Cardiac sympathetic dysfunction in an athlete's heart detected by 123I-metaiodobenzylguanidine scintigraphy. Jpn Circ J. 2001; 65(5):371-4. DOI: 10.1253/jcj.65.371. View

Matsuo S, Nakamura Y, Kinoshita M . Poststress left ventricular function in patients with coronary artery disease measured by Tl-201 ECG-gated SPECT. Exp Clin Cardiol. 2009; 7(1):30-4. PMC: 2716187. View

10.

Maron B, Gottdiener J, Epstein S . Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981; 48(3):418-28. DOI: 10.1016/0002-9149(81)90068-0. View

11.

Matsuo S, Nakamura Y, Takahashi M, Mitsunami K, Kinoshita M . Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J. 1998; 62(3):167-72. DOI: 10.1253/jcj.62.167. View

12.

Kawai C, Yui Y, Hoshino T, Sasayama S, Matsumori A . Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am Coll Cardiol. 1983; 2(5):834-40. DOI: 10.1016/s0735-1097(83)80229-0. View

13.

Devereux R, Reichek N . Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977; 55(4):613-8. DOI: 10.1161/01.cir.55.4.613. View

14.

Merlet P, Valette H, Dubois-Rande J, Moyse D, Duboc D, Dove P . Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992; 33(4):471-7. View

15.

Sisson J, Shapiro B, Meyers L, Mallette S, Mangner T, Wieland D . Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med. 1987; 28(10):1625-36. View

16.

Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T . Cardiac sympathetic activity in the asymmetrically hypertrophied septum in patients with hypertension or hypertrophic cardiomyopathy. Clin Cardiol. 2000; 23(5):365-70. PMC: 6654774. DOI: 10.1002/clc.4960230512. View

17.

Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K . Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. Am Heart J. 1990; 119(6):1329-37. DOI: 10.1016/s0002-8703(05)80183-8. View

18.

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A . Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003; 41(2):231-8. DOI: 10.1016/s0735-1097(02)02700-6. View

19.

Eisenhofer G, Friberg P, Rundqvist B, Quyyumi A, Lambert G, Kaye D . Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996; 93(9):1667-76. DOI: 10.1161/01.cir.93.9.1667. View

20.

Takatsu H, Uno Y, Fujiwara H . Modulation of left ventricular iodine-125-MIBG accumulation in cardiomyopathic Syrian hamsters using the renin-angiotensin system. J Nucl Med. 1995; 36(6):1055-61. View